Comprehensive Geriatric Assessment Identifies Significant Functional Impairments in Older Hematopoietic Cell Transplant Recipients

Rebecca L. Olin(University of California, San Francisco), Lloyd E. Damon(University of California, San Francisco), Weiyun Z. Ai(City College of San Francisco), Thomas G. Martin(University of California San Francisco Medical Center), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center), Charalambos Andreadis(University of California, San Francisco), Aaron C. Logan(University of California, San Francisco), Catherine C. Smith(University of California, San Francisco), Karin Gaensler(University of California, San Francisco), Jeffrey M. Venstrom(Foundation Medicine (United States)), Jimmy Hwang, Jeffrey L. Wolf(City College of San Francisco)
Transplantation and Cellular Therapy
February 1, 2014
10.1016/j.bbmt.2013.12.075
Cited by 10

Related Papers

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782